Status:
ENROLLING_BY_INVITATION
HRQoL Keratinocyte Carcinomas
Lead Sponsor:
University Hospital, Ghent
Collaborating Sponsors:
Erasmus Medical Center
Conditions:
Basal Cell Carcinoma
Squamous Cell Carcinoma
Eligibility:
All Genders
18-100 years
Brief Summary
Rationale: Keratinocyte skin cancer is known to influence the HRQoL in a specific way. Derived utility values are required for cost-effectiveness analyses of new interventions. However there is no sen...
Detailed Description
See protocol
Eligibility Criteria
Inclusion
- Inclusion criteria
- 1\. Patients with one or more premalignant lesion or KC diagnosed by a dermatologist or by histopathology untill 10 years previous to inclusion.
- Exclusion criteria
- Patient is younger than 18 years old or unable to provide consent.
- Patient is unable to remember the diagnosis or symptoms of their KC or premalignant lesion upon request by the doctor.
- Patient was diagnosed with a melanoma or another NMSC.
- Patient is unable to understand the task and questionnaires.
Exclusion
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
2400 Patients enrolled
Trial Details
Trial ID
NCT04814953
Start Date
July 1 2020
End Date
December 31 2025
Last Update
May 9 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, Ghent University Hospital
Ghent, Belgium, 9000
2
MC Rotterdam Department of Dermatology
Rotterdam, Netherlands